Health & Medical Health & Medicine Journal & Academic

HIV Outcomes in HBV Coinfected Individuals on HAART

HIV Outcomes in HBV Coinfected Individuals on HAART

Abstract and Introduction

Introduction


Hepatitis B virus (HBV) is more common in HIV-infected individuals than in the general population because of similar routes of transmission for viral acquisition. Current evidence suggests that HIV infection has an adverse impact on HBV-related liver disease progression, with an increase in HBV replication, reduction in the rate of clearance of serum hepatitis B e antigen, and increased risk of cirrhosis, liver-related mortality, and hepatocellular carcinoma at lower CD4 T-cell counts. Coinfection rates are estimated between 5% and 10%, with up to 40% of immunocompromised patients developing chronic infection.

Clinical studies before the general availability of highly active antiretroviral therapy (HAART) evaluating the impact of HB on HIV progression have been mixed. Some studies found no differences in HIV progression between those with and without chronic HB, whereas other studies have shown that chronic HB may negatively impact HIV progression with a significant increased risk of AIDS or death.

Studies evaluating the influence of HIV-HBV coinfection on HIV RNA suppression, immunologic CD4 cell count recovery, and clinical outcomes in individuals on HAART have been limited and conflicting, with several studies finding no difference. Several studies from HBV-endemic countries have also found no difference on HIV outcomes. Law et al showed a smaller early increase in CD4 response after HAART initiation (HI), however, this was not sustained. Hawkins et al showed that coinfected compared with monoinfected individuals had significantly lower CD4 counts throughout the period of recovery. Other studies have shown that coinfected individuals are less likely to achieve virologic suppression (VS) as compared with HIV-monoinfected individuals. Recent studies have for the most part failed to show a substantial impact of HBV coinfection on immunologic or HIV virologic responses to antiretroviral therapy (ART). Idoko et al, however, found a lower proportion of HBeAg-positive individuals achieving HIV VS at 24 weeks as compared with HBeAg-negative or HIV-monoinfected individuals, but the findings were not seen at 48 weeks. One recent study evaluating HIV outcomes during the first 3 years of ART found impaired CD4 cell recovery in hepatitis B surface antigen (HsAg)-positive and anti-HBc patients as compared with HBV-uninfected patients. Heterogeneity of available data warrants further evaluation of this key question.

Limitations and heterogeneity of results from other studies may be attributed to the small number of individuals analyzed, defining patients with chronic HB sometimes with only 1 positive test for HBsAg, or limited follow-up after HI. We sought to evaluate the impact of HBV infection in HIV-coinfected HAART recipients in a large cohort with known and limited duration of HIV infection, free access to health care, racial diversity, minimal injection drug use (IDU), and long-term follow-up.

Introduction


Hepatitis B virus (HBV) is more common in HIV-infected individuals than in the general population because of similar routes of transmission for viral acquisition. Current evidence suggests that HIV infection has an adverse impact on HBV-related liver disease progression, with an increase in HBV replication, reduction in the rate of clearance of serum hepatitis B e antigen, and increased risk of cirrhosis, liver-related mortality, and hepatocellular carcinoma at lower CD4 T-cell counts. Coinfection rates are estimated between 5% and 10%, with up to 40% of immunocompromised patients developing chronic infection.

Clinical studies before the general availability of highly active antiretroviral therapy (HAART) evaluating the impact of HB on HIV progression have been mixed. Some studies found no differences in HIV progression between those with and without chronic HB, whereas other studies have shown that chronic HB may negatively impact HIV progression with a significant increased risk of AIDS or death.

Studies evaluating the influence of HIV-HBV coinfection on HIV RNA suppression, immunologic CD4 cell count recovery, and clinical outcomes in individuals on HAART have been limited and conflicting, with several studies finding no difference. Several studies from HBV-endemic countries have also found no difference on HIV outcomes. Law et al showed a smaller early increase in CD4 response after HAART initiation (HI), however, this was not sustained. Hawkins et al showed that coinfected compared with monoinfected individuals had significantly lower CD4 counts throughout the period of recovery. Other studies have shown that coinfected individuals are less likely to achieve virologic suppression (VS) as compared with HIV-monoinfected individuals. Recent studies have for the most part failed to show a substantial impact of HBV coinfection on immunologic or HIV virologic responses to antiretroviral therapy (ART). Idoko et al, however, found a lower proportion of HBeAg-positive individuals achieving HIV VS at 24 weeks as compared with HBeAg-negative or HIV-monoinfected individuals, but the findings were not seen at 48 weeks. One recent study evaluating HIV outcomes during the first 3 years of ART found impaired CD4 cell recovery in hepatitis B surface antigen (HsAg)-positive and anti-HBc patients as compared with HBV-uninfected patients. Heterogeneity of available data warrants further evaluation of this key question.

Limitations and heterogeneity of results from other studies may be attributed to the small number of individuals analyzed, defining patients with chronic HB sometimes with only 1 positive test for HBsAg, or limited follow-up after HI. We sought to evaluate the impact of HBV infection in HIV-coinfected HAART recipients in a large cohort with known and limited duration of HIV infection, free access to health care, racial diversity, minimal injection drug use (IDU), and long-term follow-up.

SHARE
RELATED POSTS on "Health & Medical"
Improving the Recognition of Temple Syndrome
Improving the Recognition of Temple Syndrome
Is HF Underrepresented in National Mortality Statistics?
Is HF Underrepresented in National Mortality Statistics?
Check Out That Body: A Community Awareness Campaign in New York City
Check Out That Body: A Community Awareness Campaign in New York City
Immunization Training: Right or Privilege?
Immunization Training: Right or Privilege?
Pharmacist Prescribing: What Are the Next Steps?
Pharmacist Prescribing: What Are the Next Steps?
Anger Management and Stress Control for Smoking Cessation
Anger Management and Stress Control for Smoking Cessation
Influenza, Influenza-like Symptoms and Their Association With Cardiovascular Risks
Influenza, Influenza-like Symptoms and Their Association With Cardiovascular Risks
Stigma as a Cause of Population Health Inequalities
Stigma as a Cause of Population Health Inequalities
Postmenopausal Weight Change and Incidence of Fracture
Postmenopausal Weight Change and Incidence of Fracture
Portable Cushioned Operating Table Siderails
Portable Cushioned Operating Table Siderails
Benzodiazepine Use and Risk of Alzheimer's Disease
Benzodiazepine Use and Risk of Alzheimer's Disease
Effects of Sildenafil on Haemodynamics and Exercise in HF
Effects of Sildenafil on Haemodynamics and Exercise in HF
Value of Interphase FISH for the Diagnosis of t(11;14)(q13;q32)
Value of Interphase FISH for the Diagnosis of t(11;14)(q13;q32)
Pathologic Evaluation of Cryoprobe-Assisted Lumpectomy for Breast Cancer
Pathologic Evaluation of Cryoprobe-Assisted Lumpectomy for Breast Cancer
Ear Acupuncture for Acute Sore Throat
Ear Acupuncture for Acute Sore Throat
The Impact of Health Coaching on Medication Adherence
The Impact of Health Coaching on Medication Adherence
Adherence of Heart Failure Patients to Exercise
Adherence of Heart Failure Patients to Exercise
Adherence to Artemisinin Combination Therapy for Malaria
Adherence to Artemisinin Combination Therapy for Malaria
TNF Inhibitors vs Standard Therapy in Rheumatoid Arthritis
TNF Inhibitors vs Standard Therapy in Rheumatoid Arthritis
Incidence of Pancreatitis in HIV-1-Infected Individuals Enrolled
Incidence of Pancreatitis in HIV-1-Infected Individuals Enrolled

Leave Your Reply

*